Gwak, S; Arroyo-Mora, LE; Almirall, JR. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry Drug Test. Anal., 1 Feb 2015, 7 (2), 121-130. 1.1 MB. https://doi.org/10.1002/dta.1667 #8 GC,MS
Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products Drug Test. Anal., 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #23
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report) Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #1. CP 47,497
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB. LC,MS,IR,UV
Davidson, C; Opacka-Juffry, J; Arevalo-Martin, A; Garcia-Ovejero, D; Molina-Holgado, E; Molina-Holgado, F. Spicing up pharmacology: A review of synthetic cannabinoids from structure to adverse events In Adv. Pharmacol.; , Elsevier, 1 Jan 2017; pp 135–168. 458 kB. https://doi.org/10.1016/bs.apha.2017.05.001 #CP-47947
EMCDDA. New drugs in Europe, 2009, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2010. 321 kB. #4
Banister, SD; Stuart, J; Conroy, T; Longworth, M; Manohar, M; Beinat, C; Wilkinson, SM; Kevin, RC; Hibbs, DE; Glass, M; Connor, M; McGregor, IS; Kassiou, M. Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues Forensic Toxicol., 1 Jul 2015, 33 (2), 355–366. 931 kB. https://doi.org/10.1007/s11419-015-0282-9 #CP 47,497 GC,MS,NMR,IR,UV,other
Weissman, A; Milne, GM; Melvin, LS. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J. Pharmacol. Exp. Ther., 1 Nov 1982, 223 (2), 516–523. 2.8 MB. #CP-47,497
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #4
Piggee, C. Investigating a not-so-natural high Anal. Chem., 1 May 2009, 81 (9), 3205-3207. 150 kB. https://doi.org/10.1021/ac900564u #CP 47,497
Uchiyama, N; Kikura-Hanajiri, R; Shoda, T; Fukuhara, K; Goda, Y. Isomeric analysis of synthetic cannabinoids detected as designer drugs Yakugaku Zasshi, 1 Jan 2011, 131 (7), 1141–1147. 763 kB. https://doi.org/10.1248/yakushi.131.1141 #5 LC,MS,UV,other